Summary A panel of 25 different lipid agents was evaluated for in vitro activity against HT29 human colon carcinoma and HL60 promyelocytic leukaemia cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The structure-activity relationships seen with this series, including those for four sets of positional or stereoisomers, indicate that specific receptor proteins are unlikely as targets for anti-tumour lipid (ATL) action. Additional data confirm the lack of involvement of the platelet-activating factor receptor in particular and suggest that metabolic stability is a most important determinant of ATL activity. More detailed studies, with 1-O-octadecyl-2-0-methyl-rac-glycero-3-phosphocholine (ET18-OCH3) and (±)-2-{Hydroxy[tetrahydro-2-(octadecyloxy)methylfuran-2-yl]methoxylphosphinyloxy)-N,N,N,-trimethylethaniminium hydroxide (SRI 62-834), suggest three different modes of activity, depending on drug concentration and exposure time. Low doses of up to 5 jiM in standard serum-containing medium cause population growth arrest after prolonged exposure. Growth arrest was associated with a leaky G2/M block as determined by flow cytometry. These effects are reversible. Intermediate concentrations (5-40 M) were cytotoxic, causing a net reduction in cell numbers after 2-3 days. At even higher concentrations, all lipids caused rapid, direct membrane lysis. When the clonogenic assay was used to assess the effects of ATLs, most agents reduced colony formation at concentrations above 5 jIM. However, some compounds proved stimulatory at nanomolar concentrations, suggesting that they might possess mitogenic properties. These results, particularly those concerning the concentration and time dependence, may be relevant to current clinical trials with ether lipids.
Synthetic anti-tumour lipids (ATLs), including the novel alkylphosphocholine derivatives, have emerged as effective agents in model systems and are currently undergoing clinical trials (Berdel et al., 1980; Berdel, 1991; Houlihan et al., 1995) . Current preclinical and clinical experience with these agents has recently been comprehensively reviewed (Lohmeyer and Bittman, 1994) . They represent a new class of structurally distinct non-DNA-interactive anti-tumour agents whose main site of action appears to be at the plasma membrane (Berdel and Munder, 1987; Diomede et al., 1990; Grunicke, 1991) . Combination chemotherapy studies have indicated that the mechanisms of action of ATLs, DNAinteractive agents and radiation are independent (Andreesen et al., 1982; Noseda et al., 1988a; Hofmann et al., 1989; Neumann et al., 1991) . In addition to their direct effects on tumour cells, some ATLs also activate the host immune system (Talmadge et al., 1987; Hilgard et al., 1991; Pignol et al., 1992; Houlihan et al., 1995) .
The encouraging results obtained in various model systems have highlighted the therapeutic potential of ATLs. Several compounds, including ET18-OCH3, SRI 62-834, the thioether lipid BM 41.440 and hexadecylphosphocholine (HePC) (see Table I ), are scheduled for, or currently undergoing, phase I/II clinical evaluation (Lohmeyer and Bittman, 1994) . Considerable success has already been achieved with bone marrow purging (Berdel, 1991; Vogler, 1994) . Topical application of HePC in breast cancer has also produced encouraging results (Dummer et al., 1992; Unger et al., 1992) . Some responses were seen following systemic administration, and studies are ongoing, but the overall results so far obtained by oral and intravenous dosage have been disappointing (Berdel, 1990; Lohmeyer and Bittman, 1994) .
Despite extensive laboratory and clinical studies, the major molecular mechanism of action of ATLs remains unclear (see Berdel, 1991; Lohmeyer and Bittman, 1994; Houlihan et al., 1995) . Several plasma membrane proteins have been suggested as targets for ATLs, including the Na+/K+-ATPase membrane pump, Ca2+ channels, protein kinase C (PKC), phospholipase C (PLC) and PI-3-kinase (Shoji et al., 1988; Berdel, 1991; tJberall et al., 1991; Powis et al., 1992; Berggren et al., 1993) . ATLs also interfere with cellular phospholipid metabolism (Modolell et al., 1979; Berkovic et al., 1992) . In addition, they alter membrane fluidity, effect cell shape changes and permeabilise cells by membrane pore formation (Noseda et al., 1989a; Dive et al., 1991) . However, direct permeabilisation and lysis may not be the key cytotoxic lesion at lower, pharmacological doses of ATLs (Lohmeyer and Workman, 1992) . Sensitivity to ATLs has been correlated with the rate of endocytotic activity, plasma membrane cholesterol content and endogenous alkyl lysophospholipid concentration (Modolell et al., 1979; Mangold and Weber, 1987; Bazill and Dexter, 1990; Diomede et al., 1991 Diomede et al., , 1992 . ATLs also interfere with the production of infectious HIV-1 virus particles in vitro and inhibit the fusion of intracytoplasmic vesicles with the plasma membrane (Meyer et al., 1991; Kucera et al., 1990 Kucera et al., , 1993 . However, a clear concept of the molecular target of ATL activity has yet to emerge from these interesting, but diverse findings. Indeed, it is possible that there is no one single mode of action, but a series of critical events which can act in concert to inhibit tumour cell growth.
We have investigated structure-activity relationships for the in vitro activity of 25 different phospholipids related to platelet-activating factor (PAF). Proliferation assays with differing end points were performed to distinguish between the cytotoxic and/or cytostatic effects of ATLs. Cells were studied using population growth curves, MTT dye reduction and clonogenic assays. Flow cytometric cell cycle analysis provided a further insight into the cytostatic and cytotoxic mechanisms of action of ATLs. We also investigated the dose-response relationships for direct plasma membrane damage using a large selection of agents. Moreover, the potential interaction of ATLs with specific cellular receptors Ani-tumour aciviy of ether lipids M Lohmeyer and P Workman was examined. Experiments were performed on two ATLsensitive cell lines: HT29 human colon carcinoma and HL60 human promyelocytic leukaemia. Selected agents were also evaluated against the EMT6/VJ mouse mammary tumour.
Materials and methods

Cells
Human promyelocytic HL60 leukaemia cells were cultured in antibiotic-free RPMI-1640 (Gibco Biocult, Paisley, UK) containing 10% fetal calf serum (FCS) (Seralab, Crawley Down, UK) and 1 mM glutamine. HT29 human colon carcinoma cells and EMT6 mouse mammary carcinoma cells were grown in Eagle's MEM (Gibco) with 10% FCS (Seralab), glutamine and antibiotics (penicillin and streptomycin at 100 IU ml-and 100 1g ml-' respectively). Cells were mycoplasma free and maintained at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide.
Lipid agents and other reagents The compounds used are illustrated in Table I . 2, 4] triazolo- [4,3-a] Cytotoxic potency The antiproliferative potency of ATLs and related lipid agents was assessed using the MTT dye reduction assay, as described previously (Lohmeyer and Workman, 1992) .
Membrane damage
The 5'Cr radiolabel release assay was performed as described previously (Lohmeyer and Workman, 1993 were washed twice with PBS, exposed to 0.1 mg ml-' RNAse A (Sigma) for 15 min at 37°C and then diluted to t I06 cells ml'. Propidium iodide (1 pg ml 1) was added before analysis on a Beckton Dickinson FacsStar. Triplicate samples of 10 000 events each were analysed using the flow cytometer software. Compounds with differing alkyl chain length (i.e. C16 vs C18) were available for PAF, lyso-PAF and ET18-OCH3. The C18 compounds, particularly of PAF and lyso-PAF, were more cytotoxic than their C16 counterparts (see Table II ). However, the differential was not statistically significant for the more potent anti-tumour agents ET18-OCH3 and ET16-OCH3.
Lack of toxicity modulation by WEB 2086
The PAF receptor antagonist WEB 2086 was non-toxic at concentrations exceeding 250JM. At 49 JM, WEB 2086 had no effect on the cytotoxicities of any of the lipid agents tested in HT29 and HL60 cells (see Table II ). These results argue against the involvement of a WEB-sensitive PAF receptor in the cytotoxicity of PAF or its ATL analogues.
Population growth curve analysis Figure 2 illustrates the effect of continuous SRI 62-834 exposure on HL60 cells. Cytostasis occurs at 3-5 JAM and population growth arrest persists for > 7 days. Similar results were seen in HT29 cells, in agreement with their coordinate MTT data. Again, the dose-response curve is extremely steep for both cell lines with population growth hardly affected at 1 JAM, but with almost complete stasis occurring at 2-3 JAM. (Figure 3) .
Interestingly, HL60 promyelocytic cells did not differentiate in response to treatment with ATLs at these doses. Cellular differentiation was not evident under the conditions used, as judged by morphology, adhesion and flow cytometric analysis of cell shape and granularity.
We have previously shown that serum concentration affects the lytic potency of ET18-OCH3 and SRI 62-834 (Lohmeyer and Workman, 1993) . Here, we show that serum concentration also affects the non-lytic antiproliferative activity of ATLs. Reducing serum concentrations from 10% to 5.5% and 1 % results in markedly slower growth of untreated HT29 cells. Control cell numbers after 7 days were reduced to 55.0% and 9.5% respectively. After continuous exposure to various ATLs, a steep antiproliferative dose-response relationship was evident at all serum levels. The ICs values in 10%, 5.5% and 1% FCS were 1.8, 0.8 and 0.3 JAM respectively, confirming the potentiating effects of serum levels on the non-lytic antiproliferative activity of ATLs.
Cell cycle effects of ether lipids Population growth curves (e.g. Figure 2 ) show that cell numbers increase at almost the normal rate for the first 24 h after addition < 5 JAM ATL. Only after that period does a significant slowing of cell proliferation (or an increase in cell death) become apparent. This suggests that the majority of cells are able to proceed through one cell division -or complete the one they are currently in -before arresting. At > 10 JAM ATL, however, an immediate reduction in cell growth is apparent after 24 h (Figure 2) . Days after drug addition (Figure 4a-c) . This shows that cells in the G2 or M-phase were unable to proceed through mitosis to the next GI phase, accumulating instead in the G2/M compartment. The proportion of cells in S-phase was comparatively unchanged by ET18-OCH3 treatment. A large amount of DNA-containing debris was also seen routinely at 5 JAM doses (Figure 4c ). The amount of fluorescing debris increased from just over 2% in control cells to almost 35% of all 'events' collected at 5 J.M ET18-OCH3 (Figure 4c) . Thus, ATLs at > 5 gM can induce significant cellular fragmentation within 28 h. Interestingly, the debris was non-random in size and scatter characteristics (debris 'peaks' in Figure 4c ). This may suggest a controlled process of cell destruction.
Incubating cells for up to 46 h did not markedly effect further shifts in the cell cycle distribution at any given dose of ATL. The major difference observed was a significant increase in the amount of cell debris at > 5 JAM ATL. Here, up to 48.6% of 'events' constituted DNA-containing debris and cell fragments. At 2 JAM ATL, the amount of debris collected was low and similar to that after 28 h. Incubating HT29 cells for 6 h with up to 5 jAM ETl8-OCH3 did not change normal cell cycle distributions or induce debris formation (not shown). Very similar cell cycle changes were also evident in ATL-treated HL60 cells ( Figure 5 ).
Reversibility of A TL-induced growth arrest
The finding that ATLs can induce growth arrest and cellular fragmentation within 28 h led us to investigate the reversibility of ATL-induced damage. After 24 h exposure, HT29 and HL60 cells were hardly affected by < 3 gM ETI8-OCH3 and regrew as soon as the agent was removed. At 5 gAM, the population took longer to recover its normal growth rate, while recovery from 10 tM took between 70 and 90 h. The effects of 48 h exposure are illustrated in Figure 6 . HL60 cells treated with 2 gM ETI8-OCH3 were able to recover their full (Table III) . This shows that the PAF receptor is not involved in the mechanism of action leading to cell lysis.
Discussion
One of the main questions addressed in this study concerns the importance of molecular structure for ATL anti-tumour activity. The great majority of previous structure-activity studies have examined racemic compounds only, ignoring the potential importance of stereochemistry for activity Fromm et al., 1987; Herrmann and Neumann, 1987 Lipid concentration (gM) Figure 7 The effect of ET18-OCH3 (=II), lyso-PAF (E) and of this work is our finding that some ATLs can promote mitogenesis at nanomolar doses. Extending previous studies by ourselves and others, we investigate the serum dependence of the non-lytic anti-tumour activity of ATLs and the importance of interactions with cellular PAF receptors for cytotoxicity and cell lysis (Andreesen et al., 1982; Fleer et al., 1992; Lohmeyer and Workman, 1992) .
The extensive structure-activity data reported here show that the human HT29 colon carcinoma and the HL60 promyelocytic leukaemia cell line were equally sensitive to any given lipid in our panel. This similarity was seen despite the different biological origins (colon epithelial vs haematopoietic) and modes of growth (attached monolayer vs singlecell suspension). The murine EMT6 mammary carcinoma cell line proved much more resistant to both ATLs and PAF analogues than the human lines. With ATLs, the difference was about 30-fold. With PAF and lyso-PAF, little or no cytostatic effect was seen in EMT6 up to 150 JiM -a concentration 3-fold higher than the IC50 in HT29 and HL60 cells. Clearly, EMT6 cells either metabolise and detoxify ATLs more rapidly or lack the specific target(s) responsible for potency in the human lines. Decreased endocytotic activity and/or increased cholesterol levels have also been advanced as a determinant of ATL resistance (Bazill and Dexter, 1990 ; Diomede et al., 1991; reviewed in Workman, 1991). The effect is unlikely to involve species differences, since other murine cell lines such as WEHI-3B myelomonocytic leu2o2 282 kaemia and Meth A fibrosarcoma cells are sensitive to ATLs (Houlihan et al., 1987; Bazill and Dexter, 1990 ).
To date, three basic key molecular features are recognised for ATL activity: (1) an ether or thioether linked alkyl moiety at the sn-1 position of the glycerol backbone; (2) a small substituent at the sn-2 position; and (3) a phosphocholine head group at the 3-position of sn-glycerol (Fleer et al., 1990; Munder and Westphal, 1990; Vogler et al., 1993a) . However, these apparent 'rules' are being rapidly eroded as medicinal chemists prepare ever more exotic lipid compounds which nevertheless retain anti-tumour activity (Ishaq et al., 1989; Kasukabe et al., 1990; Marasco et al., 1990; Houlihan et al., 1995) .
The most important conclusion from our structureactivity data is that molecular conformation at the sn-2 position of the glycerol backbone is not an important determinant of activity. al., 1978; Hoffman et al., 1986; Breiser et al., 1987) . At the present time, we believe the most parsimonious hypothesis to be that ATLs are more potent than natural lipids because of their greater metabolic stability.
The precise molecular mode of action of ATLs remains to be elucidated. The potential involvement of a PAF receptor (Honda et al., 1991) was suggested by the close structural similarity of some ATLs to PAF. ET18-OCH3 and MCP in particular are known to antagonise PAF binding, MCP exhibiting a potent agonist activity (Shen et al., 1987) . The triazolodiazepine derivative WEB 2086 potently antagonises the various known PAF effects in vitro and in vivo (CasalsStenzel et al., 1987) and has been described as the 'reference PAF antagonist' (Page and Abbott, 1989) . Testing a larger panel of agents, we have confirmed our earlier finding (Lohmeyer and Workman, 1992) (Munder and Westphal, 1990; Berdel, 1991) PI-3-kinase, the Na+/K+-ATPase, Ca2+ channels and the epidermal growth receptor (Oishi et al., 1988; Kosano and Takatani, 1989; Powis et al., 1992; Berggren et al., 1993 (Honma et al., 1981 (Honma et al., , 1991 Vallari et al., 1988; Maurer and Hilgard, 1992) , but inhibition of differentiation has also been described in the same model system (Shoji et al., 1988; Kuo et al., 1990; Raynor et al., 1991) . Apoptosis has been observed in some leukaemic cell lines, including HL60, in response to challenge with ATLs (Diomede et al., 1993 (Diomede et al., , 1994 , but this response is not universal (Morimoto et al., 1991) . (3) As concentrations exceed 40 JAM, the detergent properties of the ATLs begin to induce direct lytic membrane damage. At these high concentrations, the toxicity differential between ATLs and naturally occurring ether lipids is progressively eroded, with all types of lipid killing cells by rapid membrane lysis.
Our results show that the recovery of cell population growth after ATL treatment is both dose and exposure time related. ATLs are widely believed to integrate into the plasma membrane and possibly other cellular membranes (Hoffman et al., 1986) . It was perhaps surprising, therefore, that growth inhibition could be removed by simply replacing the drug-containing medium with fresh, drug-free medium. This suggests a rapid equilibrium between the serum-bound and cell-associated lipid. Cells presumably recover their full growth potential by rapid 'back-exchange' onto serum proteins. This putative recovery mechanism has important implications. To be efficiently exchanged with serum proteins, the majority of ATLs must be associated with the outer leaflet of the plasma membrane. The precise location of ATLs within cell membranes has yet to be established and only little is known to date about related phosphocholine lipids (Sleight and Abanto, 1989; Andreesen et al., 1982; Bazill and Dexter, 1990) .
Interestingly, in addition to the antiproliferative effects above, we noted that some ATLs promoted clonogenic colony formation and cell proliferation in MTT assays (not shown). Submicromolar concentrations were seen to stimulate significant increases in colony counts, while concentrations above about 2 JAM reduced colony counts dramatically.
This potentially mitogenic activity has been mentioned 'in passing' (Hoffman et al., 1984; Mende et al., 1989; Sobottka et al., 1993) , but there have been no data to support the hypothesis that some ATLs can stimulate growth at nanomolar doses.
Other evidence for a potentially mitogenic role of ATLs comes from cell signalling experiments. ATLs can elicit lipidspecific calcium elevations in tumour cells (Lazenby et al., 1990; Seewald et al., 1990; Lohmeyer and Workman, 1993) . Under certain circumstances, such as at low ATL concentrations, these calcium changes may conceivably serve as mitogenic signals, thus stimulating cell proliferation. On the other hand, it should be noted that certain conventional anti-tumour drugs, such as doxorubicin, can also induce cell proliferation at very low concentrations, probably via a membrane effect (Vichi and Tritton, 1989) . It is not clear whether these results are relevant to the clinical use of ATLs, but one possibility is that they may relate especially to the observed immunostimulatory effects.
A factor of definitive clinical relevance is the schedule dependence of ATLs. Our studies highlight the importance of exposure time for the in vitro anti-tumour effectiveness of ATLs. We found that with pharmacologically relevant concentrations of ATLs, the cytostatic/cytotoxic effect generally developed after the first 24h of exposure. This 'induction period' was also noted for other ATL activities, such as the suppression of growth factor signalling (unpublished observation; Berens et al., 1988; Seewald et al., 1990) . Moreover, recovery of cell growth following 24 h of exposure was comparatively rapid. Longer exposures (> 48 h) resulted in more pronounced cytostasis/cytotoxicity, and a much delayed recovery. Under conditions of continuous exposure, 2-3 f4M ET18-OCH3 or SRI 62-834 was cytostatic, maintaining growth arrest for over 7 days. The dependence on prolonged exposure for maximal activity has also been commented upon by others (Seewald et al., 1990; Principe et al., 1992) . It is possible that the failure of some recent phase I/II clinical trials (Rodriguez et al., 1992; Verweij et al., 1992 Verweij et al., , 1993 to show activity may lie with the dose schedules used, rather than the efficacy of the drugs per se. Clearly, most of the clinical trials to date have failed to match the promise of the in vitro and in vivo preclinical studies (Lohmeyer and Bittman, 1994; Houlihan et al., 1995) . However, success has been reported for local topical administration of HePC in breast cancer (ten Bokkel Huinink et al., 1992; Khayat et al., 1993) and for bone marrow purging, where higher drug levels and longer exposures can be effected (Vogler et al., 1993b; Vogler, 1994) . Pharmacokinetic monitoring is urgently required to determine whether active concentrations of ATLs can be achieved and maintained clinically. Failure to do this could lead us to discard these mechanistically very interesting agents prematurely.
